Full-Time

Manager – Clinical Quality Assurance

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

501-1,000 employees

Develops cortisol modulators for medical conditions

Compensation Overview

$154.1k - $181.3k/yr

Senior, Expert

San Carlos, CA, USA

This is a hybrid role typically requiring on-site presence 3 days per week.

Category
QA & Testing
Quality Assurance
Required Skills
Google Cloud Platform
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Corcept Therapeutics referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • BA/BS degree in a relevant field, or equivalent experience
  • 6+ years’ clinical research experience
  • Understanding of Quality Systems that support GCP quality activities
  • Experience with advanced Microsoft Office applications (Word, Excel, PowerPoint)
  • Experience developing GCP processes for the best industry practices and training
Responsibilities
  • Lead/manage Good Clinical Practice (GCP) audits, including clinical investigative site audits, clinical vendor audits, clinical department internal audits, Trial Master File (TMF) audits, and applicable study document audits, including Clinical Study Reports (CSRs)
  • Serve as a QA representative and support clinical study teams to provide compliance advice
  • Participate in review and approval of clinical study documents and clinical SOPs / Guidance Documents
  • Manage study-specific Clinical Study Audit Plans (CSAP) compliance for the assigned program by using a risk-based approach for Corcept clinical studies
  • Review and approve investigational product (IP) temperature excursions to ensure release or rejection of IP on time
  • Lead continuous improvement of the Clinical Quality Management Systems (CQMS) and processes, including creation and revision of SOPs for GCP compliance and excellence
  • Manage and support inspection readiness activities for GCP
  • Support clinical inspections conducted by regulatory agencies, including sponsor inspections, clinical investigative site inspections, and contract research organization (CRO) inspections
  • Support GMP, GLP, and PV inspections
  • Lead clinical non-compliance event investigations and CAPA implementation
  • Perform quality metric analysis for clinical QA including study quality event trends from clinical process deviations / CAPAs to include a review of protocol deviations, safety, and other clinical data
  • Maintain a contemporary knowledge of agency and industry trends, standards, and methodologies as related to GCPs. Maintain the GCP regulatory surveillance program
  • Provide cross-training development opportunities to QA team members, and mentor/coach junior QA team members upon request or as an assigned supervisor
Desired Qualifications
  • BA/BS degree in a relevant field, or equivalent experience
  • 6+ years’ clinical research experience
  • Understanding of Quality Systems that support GCP quality activities
  • Experience with advanced Microsoft Office applications (Word, Excel, PowerPoint)
  • Experience developing GCP processes for the best industry practices and training

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is an FDA-approved medication for Cushing's syndrome, a condition caused by excessive cortisol. Corcept has created over 1,000 cortisol modulators through extensive research and development, aiming to expand their treatment options for patients with cortisol-related disorders. Unlike many competitors, Corcept emphasizes both drug development and patient education, providing resources to improve understanding and care for these conditions. The company's goal is to enhance patient outcomes by offering effective treatments and educational support.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Corcept's stock is the best performing pharma stock in 2025.
  • The MOMENTUM trial could expand Corcept's market reach.
  • Corcept's NDA filing for a new drug shows active portfolio expansion.

What critics are saying

  • Securities fraud investigations could harm Corcept's reputation and finances.
  • Teva's antitrust lawsuit may lead to legal challenges for Corcept.
  • Potential market share loss due to legal issues with Korlym.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

-3%
Business Wire
Apr 23rd, 2025
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

CORCEPT to present late-breaking data from pivotal Phase 3 ROSELLA trial of Relacorilant in platinum-resistant Ovarian Cancer at ASCO 2025.

Access News Wire
Mar 18th, 2025
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud Investigation - CORT

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.

Stock Titan
Mar 10th, 2025
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.

PR Newswire
Mar 3rd, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Insider Monkey
Feb 23rd, 2025
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.